Integrating post induction WT1 quantification and flow-cytometry results improves minimal residual disease stratification in acute myeloid leukemia

The Importance of Diagnostic Cytogenetics on Outcome in AML: Analysis of 1,612 Patients Entered Into the MRC AML 10 Trial

David Grimwade, Helen M. Walker, Fiona Oliver et al. · Blood · 1998 · 2.6K citations · Full text

Life Sciences, Hematology, Oncology +12

Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia.

Hitoshi Kiyoi, Tomoki Naoe, Yasuyuki Nakano et al. · PubMed · 1999 · 765 citations

Medicine, Genetics, Oncology +16

Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial

Jeffrey E. Rubnitz, Hiroto Inaba, Gary V. Dahl et al. · The Lancet Oncology · 2010 · 581 citations

Medicine, Hematology, Oncology +16

Real-Time Quantitative Polymerase Chain Reaction Detection of Minimal Residual Disease by Standardized <i>WT1</i> Assay to Enhance Risk Stratification in Acute Myeloid Leukemia: A European LeukemiaNet Study

Daniela Cilloni, Aline Renneville, Fabienne Hermitte et al. · Journal of Clinical Oncology · 2009 · 434 citations · Full text

Medicine, Hematology, Oncology +17

Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial

John A. Liu Yin, Michelle A. O'Brien, Robert K. Hills et al. · Blood · 2012 · 419 citations

Medicine, Molecular Medicine, Oncology +15